Imaging AI firm Brainomix is highlighting clinical results regarding its 360 e-Lung technology at the American College of Chest Physicians' (ACCP) CHEST conference in Chicago.
A study conducted by researchers at the University of Chicago, Weill Cornell Medical Center in New York, and the University of Alabama at Birmingham showed that e-Lung could have supported an earlier diagnosis of progressive pulmonary fibrosis in 62% of patients and up to 21 months earlier, according to the firm. It also found that e-Lung identified disease progression on CT in 77% of patients who had been deemed clinically stable, Brainomix said.
e-Lung consists of thousands of CT scans from academic institutions, according to the firm. It was cleared by the U.S. Food and Drug Administration (FDA) in 2024.
